Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim vs Eltrombopag for Thrombocytopenia in Wiskott-Aldrich Syndrome
NCT04371939Phase 2Unknown
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Thrombocytopenia comparing Romiplostim with Eltrombopag (2 arms). Primary endpoint: Percentage of patients with overall platelet response (complete response + partial response) at 1 month. Status: unknown.
02
Drugs
romiplostimeltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04371939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371939.